Reuters logo
9 个月内
BRIEF-Bempedoic Acid Global phase 3 clinical program to include patients on any Statin at any dose
2016年10月13日 / 中午11点47分 / 9 个月内

BRIEF-Bempedoic Acid Global phase 3 clinical program to include patients on any Statin at any dose

1 分钟阅读

Oct 13 (Reuters) - Esperion Therapeutics Inc :

* Bempedoic acid global phase 3 clinical program to include patients on any statin at any dose

* Esperion Therapeutics Inc - top-line results from 1002-035 demonstrated eight-week study met its primary endpoint

* Esperion Therapeutics - "focused on initiating both bempedoic acid global phase 3 efficacy program, cardiovascular outcomes study before year-end"

* Esperion Therapeutics Inc says also announced positive top-line results from its phase 1, open-label, clinical pharmacology study (1002-037)

* Esperion Therapeutics Inc- bempedoic acid appeared to be safe and well-tolerated, with no serious adverse events reported Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below